PHARMACEUTICAL CARE WHILE DISPENSING STANDARDIZED HERBAL MEDICINES FOR PATIENTS WITH COUGH
DOI:
https://doi.org/10.11603/2312-0967.2021.4.12634Keywords:
cough, pharmaceutical care, responsible self-medication, symptomatic therapy, technology of phytoneering, evidence-based medicineAbstract
The aim of the work. Optimization and improvement of pharmaceutical care in providing rational herbal medicine of patients at symptomatic treatment of cough with the use of herbal medicines produced by the original phytoneering technology.
Materials and Methods. The research methodology is based on the principles of objectivity and consistency. In the work a complex of general scientific and special methods: theoretical, method of generalization, systematization of data, comparison, methods of studying literary sources and analysis, etc. have been used.
Results and Discussion. The article highlights the basic principles of pharmaceutical care for patients with cough. The role of herbal medicine in the symptomatic treatment of cough is actualized and the rational choice of the optimal drug from the standpoint of evidence-based medicine is substantiated. The algorithm of pharmaceutical care of patients at symptomatic treatment of cough as one of the characteristic symptoms of inflammatory diseases of the respiratory tract and the algorithm of pharmaceutical care while choosing and dispensing the standardized herbal medicines in the dosage form of syrup for the symptomatic treatment of cough in children are presented.
Conclusions. During the pharmaceutical care of patients with cough, the pharmacist's primary recommendation of standardized herbal medicines is based on strong evidence-based data on their effectiveness and safety, as well as acceptability for use by different categories of consumers, including children.
References
Kovalenko, V.N., Sur, S.V., Zupanets, I.A. Compendium 2020 – drugs. Kyiv: Morion; 2020. Russian.
Fokkens WJ, Lund V J, Hopkins C. et al. EPOS 2020: European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(29):1–464.
Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care: acute rhinosinusitis [Unifikovanyy klinichnyy protokol pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy: Hostryy rynosynusyt] . [Electronic resource]. Available from: https://medprosvita.com.ua/unifi kovaniyklinichniy-protokol-gostriy-rinosinus-6. Ukrainian.
Vakulenko LI, Samochina II. [Features of phytotherapy in the prevention of acute bronchitis as a complication of ARVI]. Vozmozhnosti fitoterapii v profilaktike ostrogo bronkhita kak oslozhneniya ORVI]. Medical Nature. 2012;4:34–8. http://nbuv.gov.ua/UJRN/simmed_2015_5_44 Russian.
Popp M. [Acute bronchitis: Phytotherapy from the position of evidence-based medicine]. Zdorovia Ukrainy: temat. nomer «Pediatriia». 2019;4(51):23. http://www.health-ua.com . Ukrainian.
Kardosh P. [Phytotherapy in acute bronchitis: What evidence do we have?]. Zdorovia Ukrainy. 2019;8(463):43-4. http://www.health-ua.com. Ukrainian.
Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect. Control. Hosp. Epidemiol. 2013;34(1):1-14. https://doi/org/10.1086/668770. Epub 2012 Nov 27.
Kardos P. Phytotherapy in acute bronchitis: what is the evidence? Clinical Phytoscience. 2015;1:2. doi 10.1186/s40816–015–0003–2.
Chernykh VP, Zupanets IA, Lischishina OM. Protocols of Pharmaceutist (Pharmacist) [Protokoly provizora (farmatsevta)]. Kharkiv: NUPh: Zoloti storinky. 2014. Ukrainian.
Encyclopedia of herbal medicine / A. Chevallier. US: Dorling Kindersley, 2016. 336 p.
Zupanets KO, Shebeko SK, Ratushna KL. et al. Cumulative risks of excipients in paediatric phytomucolytic syrups: the implications for pharmacy practice. Sci. Pharm. 2021;89(3):32. https://doi.org/10.3390/scipharm89030032.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
